Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Bipolar depression is notoriously difficult to treat. The depressive episodes of bipolar disorder tend to be longer, more frequent, and more disabling than manic episodes, yet the medication options specifically approved for bipolar depression remain limited. Standard antidepressants carry risks of inducing mania or rapid cycling. In 2010, researchers at the National Institute of Mental Health tested whether ketamine — already showing remarkable antidepressant effects in unipolar depression — could help patients stuck in the depressive phase of bipolar disorder.
Nancee Diazgranados and colleagues conducted a randomized, double-blind, placebo-controlled, crossover trial in 18 patients with treatment-resistant bipolar depression. The study was published in Archives of General Psychiatry in 2010. All participants were maintained on therapeutic doses of lithium or valproate (mood stabilizers) throughout the trial — an important detail, as it means ketamine was tested as an add-on treatment rather than a standalone intervention.
Patients received a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) and saline placebo on separate occasions, with at least two weeks between infusions. The primary outcome was change in the Montgomery-Asberg Depression Rating Scale (MADRS) at multiple time points.
The results were significant. Within 40 minutes of ketamine infusion, patients showed improvement in depressive symptoms compared to placebo. By two hours, the effect was robust. At the 24-hour mark, 71% of patients responded to ketamine compared to 6% on placebo. The antidepressant effect persisted for approximately three days in many participants before symptoms began returning. Crucially, ketamine did not trigger manic or hypomanic switches in any participant — a key safety concern when treating bipolar depression.
For physicians who treat bipolar disorder, the Diazgranados trial addressed two critical questions. First, does ketamine work in bipolar depression specifically, or were the earlier positive trials only applicable to unipolar major depression? The answer appears to be that ketamine's rapid antidepressant effects extend to bipolar depression. Second, does ketamine cause manic switching? In this trial, it did not, though the concurrent use of mood stabilizers likely provided a protective effect.
The speed of response is particularly relevant for bipolar depression. Patients with bipolar disorder often cycle between states, and a treatment that can rapidly alleviate depression without destabilizing mood could be uniquely valuable. The current standard of care — medications like quetiapine, lurasidone, or lamotrigine — can take weeks to reach full effect, and many patients do not respond adequately.
It is important to note that ketamine is not FDA-approved for bipolar depression. The Diazgranados trial was a small proof-of-concept study, and the effects of a single dose were temporary. Repeated-dose protocols for bipolar depression have been explored in subsequent research but remain investigational.
If you have bipolar depression that has not responded to standard treatments, the Diazgranados trial provides early evidence that ketamine may be a viable option — particularly when used alongside a mood stabilizer. The rapid onset of improvement and the absence of manic switching in the trial are encouraging, though any use of ketamine in bipolar disorder should be supervised by a physician experienced in managing both the benefits and risks.
Patients with bipolar disorder considering ketamine therapy should have a candid conversation with their prescribing physician about mood stabilizer maintenance, monitoring protocols, and realistic expectations. Ketamine may provide rapid relief, but ongoing treatment planning is essential for sustained stability.
A randomized controlled trial at the NIMH found that a single dose of ketamine, added to ongoing mood stabilizer therapy, rapidly reduced depressive symptoms in patients with treatment-resistant bipolar depression. No manic switches were observed. While the evidence is preliminary and ketamine is not FDA-approved for this indication, the study supports further investigation of ketamine as a tool for one of psychiatry's most challenging conditions.
Reference: Diazgranados N, Ibrahim L, Brutsche NE, et al. "A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression." Archives of General Psychiatry. 2010;67(8):793-802. PMID: 20603451
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
